{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2F+Refractory+T-cell+Malignancies&page=25",
    "query": {
      "condition": "Relapsed/ Refractory T-cell Malignancies",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 845,
    "total_pages": 85,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2F+Refractory+T-cell+Malignancies&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2F+Refractory+T-cell+Malignancies&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T22:47:03.368Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01998035",
      "title": "Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoid Malignancies",
        "Lymphoma",
        "Hodgkin Lymphoma",
        "Non-hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "RomiDEPsin 10 MG/M2",
          "type": "DRUG"
        },
        {
          "name": "Oral 5-Azacitidine 100 MG",
          "type": "DRUG"
        },
        {
          "name": "Romidepsin 14 MG/M2",
          "type": "DRUG"
        },
        {
          "name": "Oral 5-Azacitidine 200 MG",
          "type": "DRUG"
        },
        {
          "name": "Oral 5-Azacitidine 300 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2013-11",
      "completion_date": "2020-01-06",
      "has_results": true,
      "last_update_posted_date": "2024-08-22",
      "last_synced_at": "2026-10-15T22:47:03.368Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01998035"
    },
    {
      "nct_id": "NCT00217646",
      "title": "Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Basophilic Leukemia",
        "Adult Acute Eosinophilic Leukemia",
        "Adult Acute Megakaryoblastic Leukemia",
        "Adult Acute Monoblastic Leukemia",
        "Adult Acute Monocytic Leukemia",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11",
        "Adult Acute Myeloid Leukemia With Maturation",
        "Adult Acute Myeloid Leukemia With Minimal Differentiation",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1",
        "Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL",
        "Adult Acute Myeloid Leukemia Without Maturation",
        "Adult Acute Myelomonocytic Leukemia",
        "Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA",
        "Adult Erythroleukemia",
        "Adult Pure Erythroid Leukemia",
        "Alkylating Agent-Related Acute Myeloid Leukemia",
        "Blastic Phase",
        "de Novo Myelodysplastic Syndrome",
        "Previously Treated Myelodysplastic Syndrome",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2005-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-04-28",
      "last_synced_at": "2026-10-15T22:47:03.368Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217646"
    },
    {
      "nct_id": "NCT06871410",
      "title": "Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Autologous Anti-CD83 CAR T-cells",
          "type": "DRUG"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Chest Radiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2026-02-02",
      "completion_date": "2028-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-15T22:47:03.368Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06871410"
    },
    {
      "nct_id": "NCT00538850",
      "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Fentanyl sublingual spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "INSYS Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2007-10",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2014-03-05",
      "last_synced_at": "2026-10-15T22:47:03.368Z",
      "location_count": 1,
      "location_summary": "Chandler, Arizona",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538850"
    },
    {
      "nct_id": "NCT00871689",
      "title": "Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "Up to 45 Years"
      },
      "enrollment_count": 2,
      "start_date": "2009-01",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-10-15T22:47:03.368Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00871689"
    },
    {
      "nct_id": "NCT05891197",
      "title": "A Biomarker Screening Protocol for Participants With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Non-small Cell Lung Cancer",
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Cancer Metastatic",
        "Non-Small Cell Carcinoma of Lung, TNM Stage 4",
        "Advanced Breast Cancer",
        "Advanced Lung Carcinoma",
        "NSCLC",
        "NSCLC, Recurrent",
        "NSCLC Stage IV",
        "Relapsed Cancer",
        "Relapse/Recurrence",
        "Recurrent Breast Cancer",
        "Recurrent NSCLC",
        "Platinum-resistant Ovarian Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer",
        "Endometrial Cancer",
        "Endometrioid Tumor",
        "High Grade Serous Carcinoma",
        "Ovarian Epithelial Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Lyell Immunopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2023-05-19",
      "completion_date": "2025-02-05",
      "has_results": false,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-10-15T22:47:03.368Z",
      "location_count": 1,
      "location_summary": "Rocky Mount, North Carolina",
      "locations": [
        {
          "city": "Rocky Mount",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05891197"
    },
    {
      "nct_id": "NCT01636388",
      "title": "Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkins Lymphoma"
      ],
      "interventions": [
        {
          "name": "allogeneic donor derived LMP specific cytotoxic T-lymphocyte",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "Up to 45 Years"
      },
      "enrollment_count": 2,
      "start_date": "2013-01",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-10-15T22:47:03.368Z",
      "location_count": 1,
      "location_summary": "Valhalla, New York",
      "locations": [
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01636388"
    },
    {
      "nct_id": "NCT00709033",
      "title": "T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "autologous or syngeneic PBTLs and EBV-CTLs",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 3,
      "start_date": "2009-07",
      "completion_date": "2025-05",
      "has_results": false,
      "last_update_posted_date": "2026-01-30",
      "last_synced_at": "2026-10-15T22:47:03.368Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00709033"
    },
    {
      "nct_id": "NCT01625260",
      "title": "A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "ALT-801",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Altor BioScience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2012-03-30",
      "completion_date": "2018-03-08",
      "has_results": true,
      "last_update_posted_date": "2024-07-19",
      "last_synced_at": "2026-10-15T22:47:03.368Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01625260"
    },
    {
      "nct_id": "NCT05972720",
      "title": "A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Relapsed/Refractory Large B-cell Lymphoma (LBCL)"
      ],
      "interventions": [
        {
          "name": "Fludarabine (Conditional therapy)",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide Monohydrate (Conditional therapy)",
          "type": "DRUG"
        },
        {
          "name": "firi-cel (Experimental drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CARGO Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2023-08-01",
      "completion_date": "2025-04-04",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-10-15T22:47:03.368Z",
      "location_count": 31,
      "location_summary": "Little Rock, Arkansas • Duarte, California • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05972720"
    }
  ]
}